The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
National Survey of Drug-Resistant Tuberculosis in China
Open accessAbstract
BACKGROUND: The available information on the epidemic of drug-resistant tuberculosis in China is based on local or regional surveys. In 2007, we carried out a national survey of drug-resistant tuberculosis in China. METHODS: We estimated the proportion of tuberculosis cases in China that were resistant to drugs by means of cluster-randomized sampling of tuberculosis cases in the public health system and testing for resistance to the first-line antituberculosis drugs isoniazid, rifampin, ethambutol, and streptomycin and the second-line drugs ofloxacin and kanamycin. We used the results from this survey and published estimates of the incidence of tuberculosis to estimate the incidence of drug-resistant tuberculosis. Information from patient interviews was used to identify factors linked to drug resistance. RESULTS: Among 3037 patients with new cases of tuberculosis and 892 with previously treated cases, 5.7% (95% confidence interval [CI], 4.5 to 7.0) and 25.6% (95% CI, 21.5 to 29.8), respectively, had multidrug-resistant (MDR) tuberculosis (defined as disease that was resistant to at least isoniazid and rifampin). Among all patients with tuberculosis, approximately 1 of 4 had disease that was resistant to isoniazid, rifampin, or both, and 1 of 10 had MDR tuberculosis. Approximately 8% of the patients with MDR tuberculosis had extensively drug-resistant (XDR) tuberculosis (defined as disease that was resistant to at least isoniazid, rifampin, ofloxacin, and kanamycin). In 2007, there were 110,000 incident cases (95% CI, 97,000 to 130,000) of MDR tuberculosis and 8200 incident cases (95% CI, 7200 to 9700) of XDR tuberculosis. Most cases of MDR and XDR tuberculosis resulted from primary transmission. Patients with multiple previous treatments who had received their last treatment in a tuberculosis hospital had the highest risk of MDR tuberculosis (adjusted odds ratio, 13.3; 95% CI, 3.9 to 46.0). Among 226 previously treated patients with MDR tuberculosis, 43.8% had not completed their last treatment; most had been treated in the hospital system. Among those who had completed treatment, tuberculosis developed again in most of the patients after their treatment in the public health system. CONCLUSIONS: China has a serious epidemic of drug-resistant tuberculosis. MDR tuberculosis is linked to inadequate treatment in both the public health system and the hospital system, especially tuberculosis hospitals; however, primary transmission accounts for most cases. (Funded by the Chinese Ministry of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
Lester, R. T., Ritvo, P., Mills, E. J., Kariri, A., Karanja, S., Chung, M. H., Jack, W., Habyarimana, J., Sadatsafavi, M., Najafzadeh, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61997-6 · Cited by 1,278
Gandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., van Soolingen, D., Jensen, P., & Bayona, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60410-2 · Cited by 1,018
Treatment for tuberculosis, guidelines for national programmes
Gyselen, E. A. (1994) · Health Policy · doi:10.1016/0168-8510(94)90025-6 · Cited by 708
Global Trends in Resistance to Antituberculosis Drugs
Espinal, M. A., Laszlo, A., Simonsen, L., Boulahbal, F., Kim, S. J., Reniero, A., Hoffner, S., Rieder, H. L., Binkin, N., Dye, C., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441706 · Cited by 671
MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.
(1963) · Europe PMC (PubMed Central) · Cited by 532
Wright, A., Zignol, M., Van Deun, A., Falzon, D., Gerdes, S. R., Feldman, K., Hoffner, S., Drobniewski, F., Barrera, L., van Soolingen, D., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60331-7 · Cited by 385
Global tuberculosis drug development pipeline: the need and the reality
Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J., & Wang, X. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60359-9 · Cited by 374
GUIDELINES FOR SURVEILLANCE OF DRUG RESISTANCE IN TUBERCULOSIS
Aziz, M. A., Laszlo, A., Raviglione, M. C., et al. (2003) · Cited by 290
Progress in tuberculosis control and the evolving public-health system in China
Wang, L., Liu, J., & Chin, D. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60316-x · Cited by 222
Self-citationDeterminants of drug-resistant tuberculosis: analysis of 11 countries.
Espinal, M., Laserson, K., Camacho, M., Fusheng, Z., Kim, S. J., Tlali, R. E., Smith, I., Suarez, P. G., Antunes, M. L., George, A., et al. (2001) · PubMed · Cited by 203
Tuberculosis Diagnosis — Time for a Game Change
Small, P. M., & Pai, M. (2010) · New England Journal of Medicine · doi:10.1056/nejme1008496 · Cited by 196
Menzies, D., Benedetti, A., Paydar, A., Royce, S., Pai, M., Burman, W., Vernon, A., & Lienhardt, C. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000150 · Cited by 194
Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding
Luna, J. A. C., & Antônio, J. (2010) · Cited by 190
MDR Tuberculosis — Critical Steps for Prevention and Control
Nathanson, E., Nunn, P., Uplekar, M., Floyd, K., Jaramillo, E., Lönnroth, K., Weil, D., & Raviglione, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0908076 · Cited by 189
Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis
Lew, W., Pai, M., Oxlade, O., Martin, D., & Menzies, D. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-2-200807150-00008 · Cited by 187
Guidelines for surveillance of drug resistance in tuberculosis
Gemert, W. V. (2009) · World Health Organization eBooks · Cited by 124
Text messages could hasten tuberculosis drug compliance
Barclay, E. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61938-8 · Cited by 79
Predictors of Extensively Drug-Resistant Pulmonary Tuberculosis
Kliiman, K., & Altraja, A. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00004 · Cited by 67
Risk factors for drug-resistant tuberculosis among non-US-born persons in New York City.
Clark, C. M., Li, J., Cr, D., & Ss, M. (2005) · PubMed · Cited by 23
Aguiar, F., Vieira, M. A. M. S., Staviack, A., Buarque, C. D., Marsico, A. G., Fonseca, L. M. M., Chaisson, R. E., Kristski, A., Werneck, G. L., & Mello, F. C. D. Q. (2009) · PubMed · Cited by 15
Cited by
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Murray, C. J. L., Ortblad, K. F., Guinovart, C., Lim, S. S., Wolock, T. M., Roberts, D. A., Dansereau, E. A., Graetz, N., Barber, R. M., Brown, J. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60844-8 · Cited by 975
Self-citationMultidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis
Seung, K. J., Keshavjee, S., & Rich, M. L. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017863 · Cited by 805
“In 2012, the China Centers for Disease Control and Prevention reported that 10% of China’s 1.4 million TB patients had MDR-TB, and the great majority of MDR-TB patients had never been treated for TB— evidence of unfettered human-to-human transmission (Zhao et al. 2012).”
BackgroundInfluentialDheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., Jiricek, J., Jung, J., Jeon, H. K., Cechetto, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3262 · Cited by 603
Metadata
- Authors
- Zhao, Y., Xu, S., Wang, L., Chin, D. P., Wang, S., Jiang, G., Xia, H., Zhou, Y., Li, Q., Ou, X., Pang, Y., Song, Y., Zhao, B., Zhang, H., He, G., Guo, J., & Wang, Y.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-06-07
- Volume
- 366
- Issue
- 23
- Pages
- 2161-2170
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1977881210
- Cited by
- 631
- References
- 21
- FWCI
- 39.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.